There are currently 13 active clinical trials seeking participants for Depressive Disorder, Major research studies. The states with the highest number of trials for Depressive Disorder, Major participants are California, Florida, Texas and New York.
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
NCT06559306
Recruiting
The purpose of this study is to know how well seltorexant works, and also to evaluate safety and maintenance effect of seltorexant compared with placebo as an adjunctive therapy to an antidepressant in improving depressive symptoms in participants with major depressive disorder with insomnia symptoms (MDDIS) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
ALL
Ages:
Between 18 years and 74 years
Trial Updated:
08/14/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +189 locations
Conditions: Depressive Disorder, Major
Register for Updates
Self Neuro-modulation Therapy for Major Depressive Disorder (MDD) With Anhedonia
NCT06982820
Recruiting
The purpose of this research is to learn more about a new treatment for individuals with Major Depressive Disorder (MDD) with heightened symptoms of anhedonia (i.e. loss of pleasure or interest in activities). The treatment is called Prism, and it is a software device intended for a novel form of neurofeedback training to be used in a clinic setting. During this study, the subject will use different techniques to measure brain activities, including magnetic resonance imaging (MRI) and electroen... Read More
Gender:
ALL
Ages:
Between 22 years and 75 years
Trial Updated:
08/11/2025
Locations: Novus Psychiatry, Tuscaloosa, Alabama +1 locations
Conditions: Depressive Disorder, Major
Register for Updates
Psilocybin for Major Depressive Disorder (MDD)
NCT06308653
Recruiting
Approximately 240 eligible adult participants (≥18 years old) who meet Diagnostic and Statistical Manual of Mental Disorders (DSM-5-TR) criteria for Major Depressive Disorder (MDD) will be enrolled. Participants will be randomly assigned to receive a single oral dose of Psilocybin 25 mg, Psilocybin 5 mg, or inactive placebo. The purpose of this study is to evaluate the efficacy, safety, and tolerability of Psilocybin 25 mg versus placebo in adults with MDD, as assessed by the difference between... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: University of Alabama Clinical Research Unit, Birmingham, Alabama +28 locations
Conditions: Depressive Disorder, Major
Register for Updates
A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder
NCT06785012
Recruiting
The purpose of this study is to evaluate how well JNJ-89495120 works (anti-depressant effects) and how well it is tolerated as compared to placebo on reducing the symptoms of depression in participants with major depressive disorder (MDD).
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
07/17/2025
Locations: UAB Huntsville Regional Medical Campus, Huntsville, Alabama +36 locations
Conditions: Depressive Disorder, Major
Register for Updates
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
NCT06511908
Recruiting
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective. Researchers want to know if a faster-acting drug, (2R,6R)-hydroxynorketamine (HNK), can better treat the symptoms of MDD. Objective: To test a study drug (HNK) in people with MDD. Eligibility: People aged 18 to 70 years with MDD. They must have had a screening assessment under proto... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
06/19/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action, Neurotransmitter Agents, Excitatory Amino Acid Agents, Physiological Effects of Drugs, Depressive Disorder, Major, Depressive Disorder, Depression, Mental Disorders, Mood Disorders, Behavioral Symptoms
Register for Updates
Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via Infliximab
NCT06136546
Recruiting
This study is a mechanistic randomized controlled trial that investigates whether inhibition of tumor necrosis factor signaling via intravenous infusion of infliximab improves psychomotor speed and executive functioning in depressed individuals who exhibit an inflammatory phenotype.
Gender:
ALL
Ages:
Between 25 years and 50 years
Trial Updated:
05/06/2025
Locations: Massachusetts General Hospital, Boston, Massachusetts
Conditions: Depressive Disorder, Major, Inflammation
Register for Updates
Dosing rTMS for Depression Post-SCI
NCT05553353
Recruiting
Depression is a leading cause of disability worldwide and is more commonly seen in individual's post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individuals' quality of life and recovery. It has been reported that among Veterans with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but... Read More
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/10/2025
Locations: Ralph H. Johnson VA Medical Center, Charleston, SC, Charleston, South Carolina
Conditions: Spinal Cord Injuries, Depression, Depressive Disorder, Major
Register for Updates
Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid Receptor Components of the Anti-Depressant Ketamine Response
NCT05915013
Recruiting
The proposed study will assess the combined effect of perampanel and ketamine on the anti-depressant response in individuals with treatment resistant depression. The purpose of this study is to test the hypothesis that stimulation of Alpha-Amino-3-Hydroxy-5-Methyl-4- Isoxazole Propionic Acid receptors (AMPAR) is critical to the anti-depressant response of ketamine.
Gender:
ALL
Ages:
Between 18 years and 60 years
Trial Updated:
02/04/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Depressive Disorder, Major, Post Traumatic Stress Disorder
Register for Updates
Treatment of Acute Mood Depressive Episode in Borderline Personality Disorder with RTMS
NCT04870255
Recruiting
This study evaluates the antidepressant effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), in individuals with borderline personality disorder (BPD) or trait and comorbid mood depressive disorder (MDD) or bipolar II disorder in a current mood depressive episode (MDE).
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
12/06/2024
Locations: Stanford Hospital, Stanford, California
Conditions: Depressive Disorder, Major, Borderline Personality Disorder
Register for Updates
Rapid Acting TMS for Suicide Ideation in Depression
NCT05100004
Recruiting
This study evaluates the effects of an accelerated schedule of theta-burst stimulation, termed accelerated intermittent theta-burst stimulation (aiTBS), on the neural networks underlying explicit and implicit suicidal cognition in inpatients with major depressive disorder.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
12/06/2024
Locations: Stanford Hospital, Stanford, California
Conditions: Depressive Disorder, Major, Suicide
Register for Updates
Acceptability and Feasibility of Work-Oriented Social-Cognitive Skills Training for Veterans With Serious Mental Illness
NCT05491538
Recruiting
Many individuals with serious mental illness have difficulty accurately interpreting interpersonal cues and effectively engaging in social exchanges. Difficulties related to the interpersonal aspects of work can lead to isolation, poor productivity, and job loss. The goals of this study are to: 1) adapt an evidence-based social cognitive skills intervention for work settings and use with Veterans, 2) examine the acceptability of the work focused skills training intervention, 3) assess the feasib... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/06/2024
Locations: Minneapolis VA Health Care System, Minneapolis, MN, Minneapolis, Minnesota
Conditions: Schizophrenia, Bipolar Disorder, Depressive Disorder, Major, Stress Disorder, Post-Traumatic
Register for Updates
InMotion - Telehealth Delivered Exercise Promotion to Treat Major Depression After TBI
NCT06005194
Recruiting
The purpose of this randomized controlled trial is to evaluate whether the InMotion intervention, delivered via telehealth (using a HIPAA-compliant video platform or phone), which uses evidence-based behavioral and motivational counseling to increase daily physical activity, is an effective treatment for Major Depressive Disorder (MDD) for people who are at least one year out from sustaining a traumatic brain injury (TBI). The first aim is to compare the efficacy of the InMotion intervention to... Read More
Gender:
ALL
Ages:
Between 18 years and 64 years
Trial Updated:
09/09/2024
Locations: University of Washington Medical Center, Seattle, Washington
Conditions: TBI (Traumatic Brain Injury), Depressive Disorder, Major, Clinical Depression, Mood Depressed, Physical Inactivity
Register for Updates